Hubungan ROS1 dengan Grading Histopatologi dalam Mendiagnosis Kanker Paru Karsinoma Bukan Sel Kecil di Rumah Sakit Kota Medan
Analysis of ROS1 in Diagnosing Non–Small Cell Lung Cancer Based on Histopathological Grading at Medan City Hospitals, 2024
Date
2024Author
Parinduri, Nurul Syuhada
Advisor(s)
Soeroso, Noni Novisari
Kasuma, Desfrina
Eyanoer, Putri Chairani
Metadata
Show full item recordAbstract
Introduction: Lung cancer remains the leading cause of cancer-related deaths globally, with around 85% of cases classified as non-small cell lung cancer (NSCLC). Changes in genes like EGFR, ALK, KRAS, MET, and ROS1 are important in deciding the best treatment options.
Objective: This study aimed to analyze ROS1 expression in NSCLC diagnosis based on histopathological grading.
Methods: This analytical observational study used a cross-sectional design. A total of 120 paraffin blocks from NSCLC patients were obtained from various hospitals in Medan between March 2024 and March 2025. The data were analyzed using the Chi-square test with a significance threshold of 0.05.
Results: Adenocarcinoma was the most prevalent histopathological type (75%), and ROS1 mutation was positive in 64.2% of patients. A significant relationship was observed between ROS1 mutation and histopathological grading (p=0.048), but no correlation was found between histopathological type and ROS1 mutation (p=0.742). The diagnostic accuracy (AUC) of ROS1 expression was 0.451.
Conclusion: ROS1 mutation showed a significant association with histopathological grading but not with histopathological type. Immunohistochemistry-based ROS1 testing can support NSCLC diagnosis, though its diagnostic accuracy remains limited.
Keywords: Non–Small Cell Lung Cancer, ROS1 Mutation, Histopathological Grading
